Search Results - "DeMets, David"

Challenges of Non–Intention-to-Treat Analyses by DeMets, David L, Cook, Thomas

“…Over the past 5 decades, the randomized clinical trial has become the gold standard for evaluation of the risks and benefits of new interventions, including…”
Get full text

Interpretation of the evidence for the efficacy and safety of statin therapy by Collins, Rory, Prof, Reith, Christina, FRCP (Glasg.), Emberson, Jonathan, PhD, Armitage, Jane, Prof, Baigent, Colin, Prof, Blackwell, Lisa, BSc, Blumenthal, Roger, Prof, Danesh, John, Prof, Smith, George Davey, Prof, DeMets, David, Prof, Evans, Stephen, Prof, Law, Malcolm, Prof, MacMahon, Stephen, Prof, Martin, Seth, MD, Neal, Bruce, Prof, Poulter, Neil, Prof, Preiss, David, PhD, Ridker, Paul, Prof, Roberts, Ian, Prof, Rodgers, Anthony, Prof, Sandercock, Peter, Prof, Schulz, Kenneth, Prof, Sever, Peter, Prof, Simes, John, Prof, Smeeth, Liam, Prof, Wald, Nicholas, Prof, Yusuf, Salim, Prof, Peto, Richard, Prof

“…Summary This Review is intended to help clinicians, patients, and the public make informed decisions about statin therapy for the prevention of heart attacks…”
Get full text

Incentives for Clinical Trialists to Share Data by Lo, Bernard, DeMets, David L

“…Clinical trialists' concerns about data sharing can be addressed through steps such as provision of necessary resources, appropriate acknowledgment and…”
Get full text

The Dapagliflozin And Prevention of Adverse‐outcomes in Heart Failure (DAPA‐HF) trial: baseline characteristics by McMurray, John J.V., DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D.

“…Background The aims of this study were to: (i) report the baseline characteristics of patients enrolled in the Dapagliflozin And Prevention of Adverse‐outcomes…”
Get full text

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction by McMurray, John J.V, Solomon, Scott D, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Anand, Inder S, Bělohlávek, Jan, Böhm, Michael, Chiang, Chern-En, Chopra, Vijay K, de Boer, Rudolf A, Desai, Akshay S, Diez, Mirta, Drozdz, Jaroslaw, Dukát, Andrej, Ge, Junbo, Howlett, Jonathan G, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E.A, Merkely, Béla, Nicolau, Jose C, O’Meara, Eileen, Petrie, Mark C, Vinh, Pham N, Schou, Morten, Tereshchenko, Sergey, Verma, Subodh, Held, Claes, DeMets, David L, Docherty, Kieran F, Jhund, Pardeep S, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna-Maria

“…In this randomized, placebo-controlled trial, investigators evaluated the effects of the sodium–glucose cotransporter 2 inhibitor dapagliflozin in patients…”
Get full text

Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial by Kosiborod, Mikhail N., Jhund, Pardeep S., Docherty, Kieran F., Diez, Mirta, Petrie, Mark C., Verma, Subodh, Nicolau, Jose C., Merkely, Béla, Kitakaze, Masafumi, DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Solomon, Scott D., Bengtsson, Olof, Lindholm, Daniel, Niklasson, Anna, Sjöstrand, Mikaela, Langkilde, Anna Maria, McMurray, John J.V.

“…BACKGROUND:Goals of management in patients with heart failure and reduced ejection fraction include reducing death and hospitalizations, and improving health…”
Get full text

When Can Intermediate Outcomes Be Used as Surrogate Outcomes? by DeMets, David L, Psaty, Bruce M, Fleming, Thomas R

“…This JAMA Guide to Statistics and Methods reviews how and under what conditions surrogate outcomes can replace patient-centered outcomes in randomized trials…”
Get full text

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy by Docherty, Kieran F, Jhund, Pardeep S, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, DeMets, David L, Sabatine, Marc S, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna Maria, Desai, Akshay S, Diez, Mirta, Howlett, Jonathan G, Katova, Tzvetana, Ljungman, Charlotta E A, O’Meara, Eileen, Petrie, Mark C, Schou, Morten, Verma, Subodh, Vinh, Pham Nguyen, Solomon, Scott D, McMurray, John J V

“…Abstract Aims In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and…”
Get full text

Data monitoring committee interim reports: We must get there soon by DeMets, David L, Wittes, Janet

“…Currently, too many Data Monitoring Committee Reports for interim review of trial progress are quite inadequate for Data Monitoring Committees to make informed…”
Get full text

Data Monitoring Committees — Expect the Unexpected by DeMets, David L, Ellenberg, Susan S

“…Randomized clinical trials require a mechanism to safeguard the enrolled patients from harm that could result from participation. This article reviews the role…”
Get full text

Achieving effective informed oversight by DMCs in COVID clinical trials by DeMets, David L., Fleming, Thomas R.

“…Best practices of data monitoring committees (DMCs) in randomized clinical trials are well established. Independent oversight provided by DMCs is particularly…”
Get full text

Machine Learning Algorithm Predicts Cardiac Resynchronization Therapy Outcomes: Lessons From the COMPANION Trial by Kalscheur, Matthew M, Kipp, Ryan T, Tattersall, Matthew C, Mei, Chaoqun, Buhr, Kevin A, DeMets, David L, Field, Michael E, Eckhardt, Lee L, Page, C David

“…BACKGROUND:Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in heart failure patients with reduced left ventricular function and…”
Get full text

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF) by Serenelli, Matteo, Böhm, Michael, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Solomon, Scott D, DeMets, David L, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna Maria, Anand, Inder S, Chiang, Chern-En, Chopra, Vijay K, de Boer, Rudolf A, Diez, Mirta, Dukát, Andrej, Ge, Junbo, Howlett, Jonathan G, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E A, Verma, Subodh, Docherty, Kieran F, Jhund, Pardeep S, McMurray, John J V

“…Abstract Aims Concern about hypotension often leads to withholding of beneficial therapy in patients with heart failure and reduced ejection fraction (HFrEF)…”
Get full text

Society for Clinical Trials Data Monitoring Committee initiative website: Closing the gap by DeMets, David L, Halabi, Susan, Thabane, Lehana, Wittes, Janet

Get full text

Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF by Martinez, Felipe A., Serenelli, Matteo, Nicolau, Jose C., Petrie, Mark C., Chiang, Chern-En, Tereshchenko, Sergey, Solomon, Scott D., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Ponikowski, Piotr, Sabatine, Marc S., DeMets, David L., Dutkiewicz-Piasecka, Monika, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna Maria, Jhund, Pardeep S., McMurray, John J.V.

“…BACKGROUND:The DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure) showed that dapagliflozin added to other guideline-recommended…”
Get full text

A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF) by McMurray, John J.V., DeMets, David L., Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna M., Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., McMurray, John JV, DeMets, David L, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Langkilde, Anna Maria, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Sjöstrand, Mikaela, Solomon, Scott D, Diez, Mirta, Nicolau, Jose, Katova, Tzvetana, O'Meara, Eileen, Howlett, Jonathan, Verma, Subodh, Ge, Junbo, Belohlavek, Jan, Schou, Morten, Böhm, Michael, Merkely, Bela, Chopra, Vijay, Kitakaze, Masafumi, de Boer, Rudolf A., Drozdz, Jaroslaw, Tereshchenko, Sergey, Dukat, Andrej, Ljungman, Charlotta, Chiang, Chern‐En, Petrie, Mark, Desai, Akshay, Anand, Inder, Pham, Vinh Nguyen, Pfeffer, Marc A., Pocock, Stuart, Swedberg, Karl, Rouleau, Jean L., Chaturvedi, Nishi, Ivanovich, Peter, Levey, Andrew S., Christ‐Schmidt, Heidi, Held, Claes, Varenhorst, Christoph, Christersson, Christina, Mann, Johannes, Holmgren, Pernilla, Hallberg, Theresa, Langkilde, AnnaMaria, Sjöstrand, Mikaela, Denison, Hans, Reicher, Barry, Bengtsson, Olof, Fox, Ywonne, Forsby, Mikael, Alenhag, Eva‐Lena, Nilsson, Ann, Kazanowska, Kinga, Olofsson, Eva Lavik, Karup, Cathrine, Ekedahl‐Berggren, Maria, Klockargård, Anna‐Lena, Kempe, Karin, Selvén, Mathilda

“…Background Sodium–glucose co‐transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with…”
Get full text

2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials by Hicks, Karen A., Mahaffey, Kenneth W., Mehran, Roxana, Nissen, Steven E., Wiviott, Stephen D., Dunn, Billy, Solomon, Scott D., Marler, John R., Teerlink, John R., Farb, Andrew, Morrow, David A., Targum, Shari L., Sila, Cathy A., Thanh Hai, Mary T., Jaff, Michael R., Joffe, Hylton V., Cutlip, Donald E., Desai, Akshay S., Lewis, Eldrin F., Gibson, C. Michael, Landray, Martin J., Lincoff, A. Michael, White, Christopher J., Brooks, Steven S., Rosenfield, Kenneth, Domanski, Michael J., Lansky, Alexandra J., McMurray, John J.V., Tcheng, James E., Steinhubl, Steven R., Burton, Paul, Mauri, Laura, O’Connor, Christopher M., Pfeffer, Marc A., Hung, H.M. James, Stockbridge, Norman L., Chaitman, Bernard R., Temple, Robert J., Fitter, Heather D., Illoh, Kachikwu, Cavanaugh, Kenneth J., Scirica, Benjamin M., Irony, Ilan, Brown Kichline, Rachel E., Levine, Jonathan G., Park, Anna, Sacks, Leonard, Szarfman, Ana, Unger, Ellis F., Wachter, Lori Ann, Zuckerman, Bram, Mitchel, Yale, Peddicord, Douglas, Shook, Thomas, Kisler, Bron, Jaffe, Charles, Bartley, Rhonda, DeMets, David L., Mencini, MariJo, Janning, Cheri, Bai, Steve, Lawrence, John, D’Agostino, Ralph B., Pocock, Stuart J.

“…This publication describes uniform definitions for cardiovascular and stroke outcomes developed by the Standardized Data Collection for Cardiovascular Trials…”
Get full text

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF by Jackson, Alice M., Dewan, Pooja, Anand, Inder S., Bělohlávek, Jan, Bengtsson, Olof, de Boer, Rudolf A., Böhm, Michael, Boulton, David W., Chopra, Vijay K., DeMets, David L., Docherty, Kieran F., Dukát, Andrej, Greasley, Peter J., Howlett, Jonathan G., Inzucchi, Silvio E., Katova, Tzvetana, Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Lindholm, Daniel, Ljungman, Charlotta E.A., Martinez, Felipe A., O’Meara, Eileen, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Tereshchenko, Sergey, Verma, Subodh, Jhund, Pardeep S., McMurray, John J.V.

“…BACKGROUND:In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin…”
Get full text

Genomic surveillance to combat COVID-19: challenges and opportunities by Robishaw, Janet D, Alter, Scott M, Solano, Joshua J, Shih, Richard D, DeMets, David L, Maki, Dennis G, Hennekens, Charles H

“…Although the development and increasingly widespread availability of effective and safe vaccines provides the greatest hope for the future recovery from the…”
Get full text

Updates on Hydroxychloroquine in Prevention and Treatment of COVID-19 by Hennekens, Charles H., Rane, Manas, Solano, Joshua, Alter, Scott, Johnson, Heather, Krishnaswamy, Shiv, Shih, Richard, Maki, Dennis, DeMets, David L.

Get full text